Beam Therapeutics Inc
BEAMHealthcare|Biotechnology|USA
$24.07
-0.17 (-0.68%)
Tangible Book
$12.17
Upcoming Data Readouts (11)
Sep 2026
Est. completion
NASolid Tumor, Adult
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei)
NCT07137195n=47
Oct 2026
Est. completion
NASolid Tumor, Adult
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan)
NCT07152353n=47
Oct 2026
Est. completion
NASolid Tumor, Adult
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen)
NCT07153094n=47
Dec 2026
Est. completion
P1P2Lymphoblastic Lymphoma
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
NCT05885464n=5
Dec 2026
Est. completion
Sickle Cell Trait
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
NCT06071377n=1,000
Dec 2027
Est. completion
P1P2Glycogen Storage Disease Type Ia
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
NCT06735755n=36
Feb 2028
Est. completion
P1P2Sickle Cell Disease
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
NCT05456880n=15
May 2028
Est. completion
P1P2Alpha 1-Antitrypsin Deficiency
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
NCT06389877n=106
Sep 2028
Est. completion
NAGlioma
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
NCT06397560n=28
May 2029
Est. completion
P1T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
NCT06934382n=33
Feb 2043
Est. completion